clinical trial · NCT06698575
A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes
Assembly Biosciences·phase1·completed·n = 103
Recurrent Genital Herpes Simplex Type 2ABI-1179ABI-1179 Placebo
brief summary
This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-1179 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-1179 in Part B in participants seropositive for Herpes Simplex Virus Type 2 (HSV-2) with recurrent genital herpes. Effect of food will also be evaluated in Part A.
started
Dec 8, 2024
primary completion
Jan 19, 2026
completion
Jan 19, 2026
last updated
Mar 23, 2026
official title
A Phase 1a/1b, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple Ascending Doses of ABI-1179 in Healthy Subjects and in Subjects Who Are Seropositive for Herpes Simplex Virus Type 2 With Recurrent Genital Herpes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol